The anti-Müllerian hormone: A useful tool for the diagnosis of polycystic ovary syndrome
Chaabouni, Khansa
The anti-Müllerian hormone: A useful tool for the diagnosis of polycystic ovary syndrome - 2023.
13
Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting women of reproductive age and has significant long-term health implications. Consequently, the anti-Müllerian hormone (AMH) was proposed as a helpful test to identify women with PCOS. The aim of this study was to determine an AMH cutoff value for the diagnosis of PCOS. Methods: This was a two-year cross-sectional study including women of reproductive age who had been diagnosed with PCOS according to the Rotterdam criteria (2003). The control group of healthy women was age-matched. The AMH test was performed using an electrochemiluminescence immunoassay. AMH levels were compared and evaluated using a receiver operating characteristic curve analysis. Results: A total of 130 women were enrolled in this study. Of these, 65 were diagnosed with PCOS and 65 were healthy. No significant difference was detected in body mass index between the two groups. AMH levels were significantly higher in women with PCOS (p = < 0.001). No significant difference in AMH levels was detected between PCOS phenotypes. A cutoff of 25.1 pmol/L (3.5 ng/mL) distinguished women with PCOS from the control group with a sensitivity of 74% and specificity of 72.3%. The area under the curve was 0.811 (95% CI: 0.73–0.88). Conclusions: Our study suggests that AMH has good diagnostic potential as a complement to the Rotterdam criteria for PCOS diagnosis in women of reproductive age of Tunisian origin.
The anti-Müllerian hormone: A useful tool for the diagnosis of polycystic ovary syndrome - 2023.
13
Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting women of reproductive age and has significant long-term health implications. Consequently, the anti-Müllerian hormone (AMH) was proposed as a helpful test to identify women with PCOS. The aim of this study was to determine an AMH cutoff value for the diagnosis of PCOS. Methods: This was a two-year cross-sectional study including women of reproductive age who had been diagnosed with PCOS according to the Rotterdam criteria (2003). The control group of healthy women was age-matched. The AMH test was performed using an electrochemiluminescence immunoassay. AMH levels were compared and evaluated using a receiver operating characteristic curve analysis. Results: A total of 130 women were enrolled in this study. Of these, 65 were diagnosed with PCOS and 65 were healthy. No significant difference was detected in body mass index between the two groups. AMH levels were significantly higher in women with PCOS (p = < 0.001). No significant difference in AMH levels was detected between PCOS phenotypes. A cutoff of 25.1 pmol/L (3.5 ng/mL) distinguished women with PCOS from the control group with a sensitivity of 74% and specificity of 72.3%. The area under the curve was 0.811 (95% CI: 0.73–0.88). Conclusions: Our study suggests that AMH has good diagnostic potential as a complement to the Rotterdam criteria for PCOS diagnosis in women of reproductive age of Tunisian origin.
Réseaux sociaux